STEEN Solution™ approved in China


XVIVO Perfusion has received approval of STEEN Solution™ by the China Food and
Drug Administration (CFDA). This enables the company to market and sell STEEN
Solution™ for clinical use in Kina.
CFDA has approved STEEN Solution ™ for lung transplantation, which allows sales
of STEEN Solution ™ for clinical use in lung transplants in China. China
currently accounts for less than five percent of all lung transplants in the
world, despite the large share of the world’s population, but the market has
shown rapid growth in recent years and there is a great need for more donated
lungs for lung transplantation.

"The approval of STEEN Solution ™ in China is important for future growth
because there is a great need for lung transplants and an interest in utilizing
EVLP with STEEN Solution ™ to increase the availability of usable donor lungs.
To be present early in the growth phase and establish the products increases the
chances of becoming a leader when the market matures," says Magnus Nilsson, CEO
of XVIVO Perfusion.

November 20, 2015
Gothenburg
XVIVO Perfusion AB (publ)
For further information please contact:
Christoffer Rosenblad, CFO, 1 720 616 2101,
christoffer.rosenblad@xvivoperfusion.com
For further information on XVIVO Perfusion’s business, please refer to the
company’s website, www.xvivoperfusion.com

The information was submitted for publication on November 20, 2015 at 8:30 a.m.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.
________________________________________________________________________________
_ 
_____________________________________

XVIVO Perfusion AB is a medical technology company which develops solutions and
systems for assessing and preserving organs outside the body and for selecting
usable organs and maintaining them in optimal condition pending transplantation.
The company is headquartered in Gothenburg, Sweden, and has one office in the
USA. The XVIVO share is listed on NASDAQ OMX First North and has the ticker
symbol XVIVO. More information can be found on the website
www.xvivoperfusion.com. The Certified Adviser is Redeye, www.redeye.se.
________________________________________________________________________________
_ 
_____________________________________

XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity
number 556561-0424.
Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: info@xvivoperfusion.com. Website: www.xvivoperfusion.com

Attachments

11200835.pdf